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β-Lactam	 antibiotics	 are	 of	 utmost	 importance	 when	 treating	 bacterial	 infections	 in	 the	32	
medical	 community.	 However,	 currently	 their	 utility	 is	 threatened	 by	 the	 emergence	 and	33	
spread	 of	 β-lactam	 resistance.	 The	 most	 prevalent	 resistance	 mechanism	 to	 β-lactam	34	
antibiotics	is	expression	of	β-lactamase	enzymes.	One	way	to	overcome	resistance	caused	by	35	
β-lactamases,	 is	 the	development	of	β-lactamase	 inhibitors	 and	 today	 several	 β-lactamase	36	
inhibitors	e.g.	avibactam	are	approved	in	the	clinic.	Our	focus	is	the	oxacillinase-48	(OXA-48),	37	
an	 enzyme	 reported	 to	 spread	 rapidly	 across	 the	 world	 and	 commonly	 identified	 in	38	
Escherichia	 coli	 and	 Klebsiella	 pneumoniae.	 To	 guide	 inhibitor	 design,	 we	 used	 diversely	39	
substituted	 3-aryl	 and	 3-heteroaryl	 benzoic	 acids	 to	 probe	 the	 active	 site	 of	 OXA-48	 for	40	
useful	 enzyme-inhibitor	 interactions.	 In	 the	 presented	 study,	 a	 focused	 fragment	 library	41	
containing	 49	 3-substituted	 benzoic	 acid	 derivatives	 were	 synthesised	 and	 biochemically	42	
characterized.	 Based	 on	 crystallographic	 data	 from	 33	 fragment-enzyme	 complexes,	 the	43	
fragments	could	be	classified	 into	R1	or	R2	binders	by	their	overall	binding	conformation	in	44	
relation	 to	 the	 binding	 of	 the	 R1	 and	 R2	 side	 groups	 of	 imipenem.	 Moreover,	 binding	45	
interactions	attractive	for	future	inhibitor	design	were	found	and	their	usefulness	explored	46	
by	 the	 rational	 design	 and	 evaluation	 of	 merged	 inhibitors	 from	 orthogonally	 binding	47	
fragments.	The	best	 inhibitors	among	the	resulting	3,5-disubstituted	benzoic	acids	showed	48	
inhibitory	 potential	 in	 the	 low	micromolar	 range	 (IC50	 =	 2.9	µM).	 For	 these	 inhibitors,	 the	49	
complex	X-ray	structures	revealed	non-covalent	binding	to	Arg250,	Arg214	and	Tyr211	in	the	50	
active	 site	 and	 the	 interactions	 observed	with	 the	mono-substituted	 fragments	were	 also	51	
identified	in	the	merged	structures.		52	
1 Introduction	53	
Years	 of	 overuse	 of	 antibiotics	 have	 selected	 for	 antibiotic	 resistant	 strains	 (1),	 and	 today	54	
medical	personnel	are	frequently	 forced	to	administer	 last-resort	antibiotics.	However,	 the	55	
number	of	cases	where	last-resort	antibiotics	fail	in	treatment	are	increasing	(2)	and	deaths	56	
due	 to	 antibiotic	 resistant	 infections	 are	 expected	 to	 surpass	 cancer	 deaths	 by	 2050	 (3).	57	
Bacterial	 resistance	 towards	 clinically	 important	 β-lactam	 antibiotics	 (4)	 like	 penicillins,	58	
cephalosporins	 and	 carbapenems	 originates	most	 often	 from	 the	 occurrence	 of	 β-lactam-59	
hydrolysing	enzymes	–	the	β-lactamases.	60	
The	β-lactamase	enzymes	are	of	ancient	origin	 (5)	and	today	over	2600	enzymes	spanning	61	






The	 class	 D	 SBLs	 are	 characterized	 by	 a	 hydrophobic	 environment	 in	 the	 active	 site,	 that	68	
facilitates	the	carboxylation	of	a	lysine	residue.	The	N-carboxylated	lysine	plays	a	critical	role	69	
in	 the	 substrate	 hydrolysis	 (10).	 Originally,	 the	 OXAs	 were	 believed	 to	 have	 a	 limited	70	
substrate	 profile	 only	 hydrolysing	 penicillins,	 but	 with	 the	 emergence	 of	 carbapenem-71	
-3-	
	
hydrolysing	 OXA	 variants,	 e.g.	 OXA-23,	 OXA-24	 and	 OXA-48,	 their	 clinical	 relevance	 has	72	
increased	 (11).	OXA-48	was	 reported	 for	 the	 first	 time	 in	 2001	 and	has	 since	 then	 spread	73	








urinary	 tract	and	 intra-abdominal	 infections	 (15).	However,	 the	 inhibition	 level	of	different	82	
class	 D	 β-lactamases	 by	 avibactam	 varies	 (16,17).	 With	 the	 first	 reports	 of	 resistance	 to	83	
avibactam	published	(18),	one	can	speculate	that	it	will	only	be	a	matter	of	time	before	class	84	
D	β-lactamases	show	resistance	to	avibactam	as	well.		85	
The	 development	 of	 new	OXA	 inhibitors,	 either	with	 a	 different	 enzyme-inhibition	 profile	86	
compared	 to	 existing	 inhibitors,	 or	 as	 alternative	 when	 resistance	 to	 existing	 inhibitors	87	
arises,	is	of	importance.	We	have	previously	reported	a	fragment-based	screening	approach	88	










In	 this	 study,	 we	 describe	 the	 use	 of	 small	 mono-substituted	 fragments	 -	 analogues	 of	99	
fragment	1	-	as	probes	to	explore	the	OXA-48	binding	site.	The	aim	was	to	identify	fragment-100	
enzyme	interactions	in	the	two	alternate	binding	pockets	of	the	active	site	of	OXA-48,	which	101	
could	be	of	general	 interest	 for	 the	design	of	OXA-48	 inhibitors.	We	wanted	to	exploit	 the	102	
ability	of	small	fragments	to	efficiently	explore	the	binding	pocket	as	they	are	less	restricted	103	
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process	more	work-efficient.	 Furthermore,	 we	wanted	 to	 translate	 the	 knowledge	 gained	106	
into	the	rational	design	of	di-substituted	inhibitors	related	to	compound	2	circumventing	the	107	
laborious	preparation	of	a	large	library	of	elaborated	inhibitors.	108	
Towards	 this	 goal,	we	prepared	a	 focused	 fragment	 library	 containing	3-aryl	benzoic	acids	109	
decorated	 with	 a	 wide	 range	 of	 polar	 groups	 and	 a	 number	 of	 3-heteroaryl	 benzoic	 acid	110	
derivatives.	In	total	49	fragments	were	tested	for	inhibitory	activity	against	OXA-48	and	the	111	
binding	 conformations	 of	 33	 fragment-enzyme	 complexes	 were	 analysed	 by	 X-ray	112	
crystallography.	Based	on	the	structural	information,	fragments	could	be	classified	according	113	
to	 their	 preferred	 binding	 pocket	 and	 useful	 fragment-enzyme	 interactions	 e.g.	 hydrogen	114	
bonds	were	 identified.	Moreover,	 several	new	orthogonally	binding	 fragments	were	 found	115	
leading	 to	 the	 design	 of	 symmetrically	 and	 unsymmetrically	 di-substituted	 inhibitors	 with	116	






(Table	 1).	 The	 fragments	 generally	 fulfilled	 the	 demands	 of	 libraries	 for	 fragment-based	123	
ligand	 design	 (MW	 <	 300,	 clogP	 <	 3,	 hydrogen	 bond	 acceptor/donors	 <	 3)	 (20).	 For	 the	124	
synthesis,	a	strategy	based	on	the	Suzuki-Miyaura	(SM)	cross-coupling	reaction	to	 join	two	125	
sp2–hybridized	 carbons	 was	 employed	 (21).	 Two	 alternate	 coupling	 strategies	 were	126	






according	 to	 standard	 acylation	 and	 sulphonylation	 protocols.	 The	 NH-tetrazol-5-yl-133	
substituted	arylbromides	(starting	material	for	fragments	26a	and	26b)	were	prepared	by	a	134	
[3+2]	intermolecular	cycloaddition	of	3-	or	4-bromobenzonitrile	with	trimethyl	silyl	azide	in	135	




























78%	 90	 170	 0.35	 11b*	 	
A	




67%	 170	 300	 0.33	 12a*	
	
A	




94%	 50	 175	 0.38	 12b	 	
A	




98%	 110	 110	 0.35	 13*	 	
B	




39%	 470	 170	 0.29	 14*	
	
A	




84%	 900	 230	 0.25	 15a	 	
B	




98%	 250	 123	 0.30	 15b	 	
B	




98%	 360	 226	 0.28	 16a	 	
B	




86%	 150	 250	 0.31	 16b	 	
B	




91%	 400	 1000	 0.28	 17*	
	
Ba,	c	




68%	 130	 170	 0.34	 18	
	
Ba,	c	




98%	 130	 240	 0.34	 19a	
	
Ba,	c	




78%	 360	 312	 0.30	 19b	
	
Ba,	c	




57%	 210	 200	 0.27	 20	
	
Ba,	c	




54%	 260	 144	 0.26	 21a*	
	
A	




98%	 380	 280	 0.27	 21b*	
	
A	




98%	 260	 220	 0.28	 22	
	
Ba,	b	
87%	 130	 130	 0.27	
*	 X-ray	 structure	 of	 fragment-enzyme	 complex	 available.	 a	 Reaction	 in	 anhydrous	 THF	 instead	 of	142	
dioxane:water	as	solvent;	b	XPhos-Pd	G2	as	catalyst	instead	of	PdCl2(PPh3)2;	c	PdCl2(dppf)	as	catalyst	143	











































































46%	 230	 170	 0.24	 29	 	
B	




34%	 520	 190	 0.22	 30	 	
B	




34%	 250	 140	 0.25	 31	 	
B	




15%	 1300	 ˃1000	 0.20	 32	 	
A	




98%	 60	 70	 0.30	 33	 	
B	




98%	 36	 70	 0.30	 34	
	
B	




67%	 110	 400	 0.30	 35*	 	
A	




87%	 240	 160	 0.27	 	 	 	 	 	 	
*	 X-ray	 structure	 of	 fragment-enzyme	 complex	 available.	 a	 Reaction	 in	 anhydrous	 THF	 instead	 of	147	
dioxane:water	as	solvent;	b	XPhos-Pd	G2	as	catalyst	instead	of	PdCl2(PPh3)2;	c	PdCl2(dppf)	as	catalyst	148	





efficient	 catalysts	 (XPhos-Pd	G2	or	 PdCl2(dppf))	 and	water-free	 conditions	 (anhydrous	 THF	154	
instead	 of	 dioxane/water)	 were	 successfully	 employed	 to	 solve	 reactivity	 and	 solubility	155	
problems	 and	 to	 prevent	 hydrolysis	 for	 base	 sensitive	 products	 (9	 and	 24).	 However,	 for	156	





To	 study	 inhibitor	properties	 like	activity	and	enzyme	 interactions	of	merged	 fragments,	 a	162	
small	series	of	symmetrical	and	unsymmetrical	3,5-disubstituted	benzoic	acids	was	designed	163	
(vide	infra)	and	prepared.	The	synthesis	of	symmetrical	3,5-disubstituted	compounds	36	and	164	
38	 was	 achieved	 under	 the	 conditions	 established	 for	 the	 coupling	 of	 mono-substituted	165	
fragments	 using	 Pd2(dba)3/XPhos	 or	 XPhos-Pd	 G2	 as	 catalysts	 (Scheme	 1)	 (19).	 The	 di-166	
substituted	 coupling	 products	 36	 and	 38	 were	 obtained	 from	 3,5-dibromobenzoic	 acid	 as	167	
starting	material	and	an	 increased	amount	of	 the	boronic	acid	derivative	 (2	equiv.)	 in	54%	168	


















For	 the	 synthesis	 of	 unsymmetrical	 3,5-disubstituted	 benzoic	 acids	 39,	 the	 sequential	177	
addition	of	two	different	aryl	boronic	acids	under	the	previously	established	conditions	gave	178	




to	 take	advantage	of	 the	 faster	coupling	reaction	of	aryl	 iodides	when	compared	with	aryl	183	
bromides	 and	 thereby	 to	 prevent	 formation	 of	 symmetrical	 disubstituted	 by-products	184	
(Scheme	 2).	 Investigation	 of	 the	 chemoselective	 coupling	 of	 3-iodo-5-bromobenzoic	 acid	185	
with	quinolin-6ylboronic	acid	pinacol	ester	to	form	mono-substituted	 int-40	showed	that	a	186	
second,	 unwanted	 coupling	was	 not	 easily	 prevented	 and	 a	 careful	 fine	 tuning	 of	 catalyst	187	
(RuPhos-Pd	G3,	XantPhos-Pd	G3,	Sphos/Pd2(dba)3,	Xphos/Pd2(dba)3,	SPhos-Pd	G3,	XPhos-Pd	188	
G2,	 Pd2(dppf)Cl2),	 solvent	 (toluene/water,	 anhydrous	 THF,	 dioxane/water,	 tert-butanol),	189	
reaction	temperature	(40–80	°C)	and	time	(10–48	h)	was	initiated	(Table	SI1,	see	supporting	190	
information).	 The	 composition	 of	 the	 crude	 reaction	mixtures	with	 respect	 to	mono-	 and	191	
disubstituted	 products	 as	 well	 as	 unreacted	 starting	 material	 was	 determined	 by	 mass	192	
spectrometry	 (MS).	 The	most	 chemoselective	 catalysts	were	XantPhos-Pd	G3,	 Pd2(dppf)Cl2	193	
and	 SPhos/Pd2(dba)3	 showing	 good	 selectivity	 for	 the	 aryl	 iodide	 when	 the	 reaction	 was	194	
performed	with	K3PO4	 as	base	 in	dioxane/water	 at	 60	 °C	 for	 24	hours	 (Scheme	2).	At	 this	195	


























Scheme	 2:	 Preparation	 of	 unsymmetrical	 3,5-disubstituted	 benzoic	 acids.	 Reagents	 and	202	
conditions:	39:	i.	X	=	Br,	3-acetamidophenylboronic	acid	(0.75	equiv.),	PdCl2(PPh3)2	(10	mol%),	203	
dioxane:water	 (1:1),	 60	 °C;	 ii.	 pyridin-4-ylboronic	 acid	 (1.2	 equiv.),	 PdCl2(PPh3)2	 (10	mol%),	204	
dioxane:water	 (1:1),	60	°C;	 int-40:	X	=	 I,	quinolin-6-ylboronic	acid	pinacol	ester	 (2.0	equiv.),	205	









(µM)/LE:	 60/0.24),	 21a	 (IC50	 (µM)/LE:	 35/0.33),	 26b	 (IC50	 (µM)/LE:	 36/0.30)	 and	 35	 (IC50	215	
(µM)/LE:	 35/0.42)	 showed	 an	 order	 of	 magnitude	 stronger	 inhibition	 and	 were	 the	most	216	
potent	 fragments.	 Even	 though	 there	 are	 some	 discrepancies	 between	 the	 inhibition	 and	217	
binding	 data,	 the	 same	 trends	 are	 maintained	 when	 comparing	 similar	 compounds,	218	
indicating	that	the	compounds	indeed	bind	specifically	to	one	site	of	the	enzyme.	219	
2.2.2 Structural	analysis	of	3-substituted	benzoic	acids	220	
To	 evaluate	 the	 binding	 poses	 of	 our	 fragments,	 enzyme-fragment	 complexes	 for	 x-ray	221	
crystallographic	 analysis	 were	 prepared.	 Rewardingly,	 33	 out	 of	 49	 fragments	 were	222	
successfully	soaked	with	OXA-48	and	yielded	crystal	structures	with	resolution	high	enough	223	
to	warrant	placement	of	the	inhibitor	in	the	electron	density	(Table	1).	In	addition,	a	crystal	224	
structure	 of	 OXA-48	 in	 complex	 with	 the	 substrate	 imipenem	 was	 obtained	 to	 better	225	
understand	substrate	binding	and	to	compare	substrate	and	fragment	binding	interactions.	226	
The	 crystal	 structure	 of	 the	 acyl-enzyme	 complex	 of	 OXA-48	 with	 imipenem	 (Fig.	 2A)	227	
revealed	a	conformation	close	to	previously	observed	conformations	with	OXA-13	(PDB-ID:	228	
1h5x).	 In	 the	 complex	 the	 ring-opened	 imipenem	 was	 bound	 to	 OXA-48	 covalently	 with	229	
continuous	electron	density	from	the	hydroxyl	group	of	Ser70.	There	was	an	ionic	bond	from	230	
the	carboxylate	group	of	imipenem	to	the	guanidine	group	of	Arg250.	The	carbonyl-group	of	231	
the	now	ring-opened	β-lactam	ring	was	positioned	 in	 the	oxyanion-hole	 forming	hydrogen	232	

































situated	 in	 the	 cleft	 defined	by	 Ile102,	 Tyr211,	 Leu247	and	Thr213	and	 this	 region	will	 be	236	
called	 the	 R2	 site.	 The	 R1	 and	 R2	 side	 chains	 of	 imipenem	 (Fig.	 2A)	 had	 the	 same	 overall	237	
directions	 as	 the	 pyridinyl	 substituents	 in	 the	 two	 overlapping	 binding	 conformations	238	
observed	with	our	initial	hit	3-pyridin-4-ylbenzoic	acid	1	(19).		239	




way	that	also	Thr209	 (fragments	9b,	28,	35),	Lys208	 (fragment	34)	or	both	 (fragment	26a)	244	
participated	in	binding.		245	
Another	 common	 feature	 found	 in	 almost	 all	 crystal	 structures,	 except	 for	 fragments	21a	246	










N-acetamide	 substituted	 phenyl	 ring	 in	 compound	 21a	 (B).	 Yet,	 most	 of	 the	 tested	 3-257	
































(Table	 1),	 as	 the	 structural	 differences	 of	 the	 fragments	 relate	 to	 this	 group	 i.e.	 3-(2-266	
methyl)phenylbenzoic	acid	3a	will	be	described	as	2-methylphenyl	substituted	fragment.		267	




but	again	we	saw	that	more	 favourable	van	der	Waals	 interactions	gave	higher	affinity	 for	272	
the	2-hydroxyphenyl	substituted	4a.	The	4-hydroxy	 isomer	4c	had	an	unfavourable	solvent	273	
exposure	of	the	hydroxyl	group.	Adding	a	methylene	bridge	yielding	3-hydroxymethylphenyl	274	
5	 (IC50	 (µM)/LE:	900/0.25)	did	not	 lead	 to	any	 favourable	 interactions.	The	methoxyphenyl	275	
fragments	 6a–c	 (IC50	 (µM)/LE:	 250/0.30,	 360/0.28	 and	 150/0.31)	 shared	 the	 canonical	 R2	276	
binding	 pose.	 The	 methoxy	 group	 of	 the	 2-substituted	 6a	 appeared	 more	 shielded	 from	277	
solvent	exposure	than	in	6b	and	6c,	yet	the	methoxy	group	did	not	seem	to	make	any	strong	278	
contacts.	 The	 weak	 inhibition	 seen	 with	 methyl	 thioether	 7	 (IC50	 (µM)/LE:	 400/0.28)	279	
corresponded	 to	 the	 results	 observed	 with	 the	 methoxy	 ethers	 6.	 The	 fluorophenyl	280	
substituted	 8a–c	 (IC50	 (µM)/LE:	 130/0.34,	 130/0.34	 and	 360/0.30)	 had	 nearly	 identical	281	
binding	 poses.	 The	 4-substituted	 8c	 gave	 the	 highest	 IC50	 value,	 most	 likely	 due	 to	 the	282	
solvent	 exposed	 fluorine.	 The	 2-substituted	 8a	 seemed	 more	 favourable	 based	 on	 the	283	
decreased	 solvent	 exposure	 of	 the	 fluorine	 atom,	 however,	 the	 difference	 to	 8b	 was	284	
negligible	only	observed	by	SPR.		285	
The	 methoxyacetylphenyl	 esters	 9a+b	 (IC50	 (µM)/LE:	 210/0.27	 and	 260/0.26)	 showed	 no	286	
clear	additional	 interactions	 in	 the	complex	structures	with	OXA-48,	and	 the	methyl	group	287	
appeared	 to	 be	 unfavourably	 exposed	 to	 the	 solvent.	 The	 corresponding	 4-acetylphenyl	288	
substituted	 10	 (IC50	 (µM)/LE:	 380/0.27)	 and	 carbamoylphenyl	 substituted	 11a+b	 (IC50	289	
(µM)/LE:	260/0.28	and	180/0.29)	gave	generally	weak	 inhibition	 indicating	 that	a	 carbonyl	290	
group	attached	to	the	aromatic	ring	was	not	contributing	to	binding.	No	complex	structures	291	
are	 available	 for	 10	 and	 11a,	 but	 the	 complex	 structure	 of	 4-carbamoylphenyl	 11b	was	292	
similar	 in	 conformation	 to	 the	 esters	9a+b.	 Slightly	 tighter	 binding	was	observed	with	 the	293	
meta-substituted	 sulfone	12a	 (IC50	 (µM)/LE:	120/0.29),	which	also	 shares	 the	 same	overall	294	
conformation.	295	
The	4-aminophenyl	 substituent	of	13	 (IC50	 (µM)/LE:	330/0.30)	did	not	appear	 to	make	any	296	





completely	 exposed	 to	 the	 solvent.	 The	 larger	 phenyl	 4-sulfonamidophenyl	 substituted	302	






containing	 fragment	 21a	 (Figure	 3),	 however,	 showed	 a	 10-fold	 increased	 inhibition	 (IC50	307	
(µM)/LE:	 	35/0.33).	The	complex	structure	of	OXA-48	with	 fragment	21a	 revealed	 that	 the	308	










µM	 (B).	 The	 crystal	 structure	 of	 the	 complex	 OXA-48:21a	 with	 an	 omit-type	 polder-map	319	




a	 hydrocarbon	 linker	 between	 the	 phenyl	 ring	 and	 the	 amino,	 sulfonamido	 or	 acetamido	324	
groups	of	13,	18	and	21.	The	amines	15	and	16,	the	sulfonamides	19	and	20,	the	amides	22,	325	
23a+b	 and	 the	 acetate	 24	 are	 more	 flexible,	 thus,	 increasing	 the	 potential	 of	 hydrogen	326	
-12-	
	
bonding.	 However,	 none	 of	 these	 fragments	 showed	 substantially	 improved	 binding	 (IC50:	327	
110–1000;	LE:	0.19–0.30).	Moreover,	the	crystal	structures	of	the	amides	22,	23a+b	and	the	328	
acetate	 24	 (IC50	 (µM)/LE:	 230/0.24,	 520/0.22	 and	 250/0.25)	 did	 not	 show	 any	 specific	329	
interactions	for	the	functional	groups.	330	
In	 fragments	 26a	 and	 26b	NH-tetrazole	 substituted	 phenyl	 rings	 were	 investigated	 as	 Ar	331	
substitutents.	 Introducing	 the	 weakly	 acidic	 tetrazol-5-ylphenyl	 substituent	 in	 either	 3-332	


















polder-map	 (2.5σ)	 (C)	 and	 a	 2D-representation	 of	 the	 protein:compound	 complex	349	
interactions.	(D).	350	
A	number	of	heterocyclic	aryl	substituents	were	also	evaluated	(fragments	25,	28–35).	With	351	
some	exceptions	of	 the	pyridinyls	29	 and	35	 (IC50	 (µM)/LE:	170/0.33	and	35/0.42)	most	of	352	
these	 fragments	 showed	 only	 weak	 inhibition.	 The	 quinolin-7-yl	 substituted	 fragment	 28	353	
(IC50	 (µM)/LE:	 	240/0.30)	did	maintain	 the	overall	 conformation	of	 the	previous	R2	binding	354	
fragments	(Figure	5),	and	so	did	the	corresponding	naphtalen-2-yl	substituted	fragment	27	355	
(IC50	 (µM)/LE:	 110/0.29).	 In	 the	 same	manner	 the	 indol-5-yl	 substituted	 fragment	34	 (IC50	356	
(µM)/LE:		310/0.27)	did	show	acceptable	binding,	yet	no	specific	interaction	except	for	the	π-357	
stacking	 with	 Tyr211.	 In	 our	 previous	 paper,	 we	 investigated	 pyridin-4-yl	 and	 pyridin-3-yl	358	
substituted	fragments	(19)	,	and	both	inhibited	OXA-48	with	the	same	potency	(IC50	(µM)/LE:	359	
250/0.32).	The	pyridin-2-yl	 substituted	 fragments	35	 (IC50	 (µM)/LE:	 	35/0.41)	showed	a	10-360	
fold	 improvement	 in	 binding	 (Fig.	 6A	 and	 B).	 In	 the	 crystal	 structure,	 two	 alternative	361	
conformations	were	observed	(Fig.	6C).	One	conformation	was	the	canonical	with	π-stacking	362	
of	 the	 pyridinyl	 ring	 with	 Tyr211	 occupying	 the	 R2	 site	 (Fig.	 6E),	 but	 in	 the	 other	363	
conformation	 the	 pyridinyl	 ring	 was	 orientated	 to	 the	 R1	 site.	 The	 second	 conformation	364	
showed	a	hydrogen	bond	from	the	protonated	N	atom	in	the	pyridine	ring	to	the	backbone	365	









analyses	 (23).	 Fragment	 35	 showed	 the	 best	 ligand	 efficiency	 (IC50	 (µM)/LE:	 35/0.42),	 but	373	





Figure	 6:	 Compound	35	 bound	 in	 the	 two	 alternate	 conformations.	 The	 IC50-value	 (A)	was	379	
determined	to	be	35	µM,	while	the	KD	was	found	to	be	159	µM	(B).	The	crystal	structure	of	380	
the	complex	OXA-48:35	with	an	omit-type	polder-map	(2.5σ)	(C)	and	a	2D-representation	of	381	
the	 protein:compound	 complex	 interactions.	 (D	 for	 green	 colored	 conformation,	 E	 for	382	
magenta	colored	conformation).		383	
2.2.3 NMR	studies	384	
In	 order	 to	 evaluate	 the	 fragment-enzyme	 binding	 in	 solution,	 a	 13C	 NMR	 experiment	 for	385	
OXA-48	was	developed	based	on	previous	studies	 (24,25).	OXA	enzymes	can	be	selectively	386	
carbamylated	 with	 bicarbonate	 at	 an	 active	 site	 lysine	 to	 provide	 the	 corresponding	387	
carbamic	acid	(24,26,27).	For	OXA-48	the	carbamylated	residue	is	Lys73,	which	is	situated	in	388	
the	 R1	 site	 (Fig.	 2B).	 By	 using	 13C-labeled	 sodium	bicarbonate	 (NaH13CO3),	 a	 13C	 atom	was	389	
-15-	
	










163.95	 ppm	 as	 a	 broad	 signal	 (Fig.	 7E),	 which	 is	 in	 good	 agreement	 with	 the	 reported	400	
chemical	 shift	 for	 carbamylated	 OXA-48	 (28).	 In	 addition,	 two	 unassigned	 signals	 were	401	
observed	at	 164.04	ppm	similar	 to	 the	 results	 reported	 for	 carbamylation	of	OXA-58	 (27).	402	
Here	 the	 authors	 speculated	 that	 the	 unassigned	 signal	 may	 be	 related	 to	 a	 second	403	
carbamylation	site	(27).		404	
On	 addition	 of	 R1	 binding	 fragment	 21a	 and	 inhibitor	 2,	 the	 13C	 chemical	 shifts	 of	 the	405	
carbamate	signal	were	consistently	deshielded	 in	both	experiments	 (δ	=	164.25,	Dd =	0.28	406	
ppm,	Fig.	7E	and	7F).	These	findings	support	that	the	compounds	bind	competitively	in	the	407	
active	 site.	 Moreover,	 the	 observed	 chemical	 shift	 perturbation	 indicates	 that	 the	408	
compounds	occupy	the	R1	site	as	found	in	the	crystal	structures.		The	R2	binding	fragment	28	409	
showed	 a	 similar	 deshielding	 of	 the	 carbamate	 signal	 though	 at	 a	 smaller	 amplitude	 (δ	 =	410	
164.13,	Dd =	0.16	ppm,	Fig.	7D)	supporting	that	the	fragment	binds	in	the	active	site,	while	411	
fragment	35,	which	was	identified	as	R1	or	R2	binder,	only	slightly	affected	the	chemical	shift	412	
(δ	 =	 164.00,	 Dd =	 0.04	 ppm,	 Fig.	 7C).	 The	 observed	 chemical	 shift	 perturbations	 for	413	
fragments	28	 and	35	may	 indicate	 that	 fragment	28	 has	an	effect	on	carbamylated	Lys73,	414	





ppm	 would	 be	 expected,	 even	 for	 a	 µM	 binder	 (29).	 This	 was	 supported	 by	 the	 crystal	420	
structures	of	OXA-48	 indicating	that	the	Lys73	carbamic	acid	was	preoccupied	 in	hydrogen	421	
bonding	 to	 Trp157	 and	 was	 not	 affected	 by	 ligand	 binding.	 The	 observed	 consistent,	 but	422	
rather	subtle,	deshielding	of	the	Lys73	carbamic	acid	(δ	=	164.25,	Dd =	0.28	ppm,	Fig.	7E	and	423	
7F)	 for	 our	 R1	 binding	 fragments	 can	 possibly	 be	 explained	 by	 an	 anisotropic	 magnetic	424	
deshielding	 by	 the	 edge	 of	 the	 aromatic	 rings	 of	 these	 fragments,	which	were	 positioned	425	
roughly	5	Å	away	from	the	reporter	carbon	for	R1	binding	fragments.	Moreover,	amplitude	426	
of	 the	chemical	 shift	perturbation	observed	with	R1	binding	 fragments	21a	 and	 inhibitor	2	427	








48	with	13C	 labeled	bicarbonate	and	fragment	28	 (D);	OXA-48	with	13C	 labeled	bicarbonate	434	
and	 fragment	 21a	 (E);	 OXA-48	with	 13C	 labeled	 bicarbonate	 and	 3,5-di(4-pyridinyl)benzoic	435	











An	 overlay	 of	 fragment	 21a	 as	 well	 as	 26b	 with	 several	 R2	 binders	 identified	 the	447	


















Figure	9:	Superimpositions	of	 the	binding	poses	observed	 for	21a/28	 (A),	21a/1	 (B,	1:	PDB-454	
ID:5dva)	 and	 26b/35	 (C)	 showing	 some	 of	 the	 possible	 combinations	 for	 3,5-disubstituted	455	
benzoic	acids.	456	
The	3,5-disubstituted	compounds	36–40	were	evaluated	for	their	 inhibitory	activity	against	457	
OXA-48	 as	 measured	 by	 their	 IC50,	 Kd	 and	 LE	 and	 complex	 structures	 with	 OXA-48	 and	458	
compounds	36,	38	and	40	were	obtained	(Table	2).	The	merged	compounds	37,	38	and	39	459	
(IC50	 (µM)/LE:	 110/0.19,	 48/0.21,	 100/0.22)	 failed	 to	 adequately	 maintain	 the	 binding	460	
interactions	as	the	IC50	values	were	at	a	similar	level	as	the	corresponding	mono-substituted	461	
fragments	28,	1	and	21a	 (IC50	 (µM)/LE:	240/0.33,	250/0.32	and	35/0.33).	When	comparing	462	
the	 IC50	values	of	compounds	36,	37	and	40	 (IC50	 (µM)/LE:	2.9/0.27,	48/0.21	and	2.9/0.27)	463	
with	 the	 corresponding	 fragments	 21a,	 21b	 and	 28	 (IC50	 (µM)/LE:	 35/0.33,	 450/0.26,	464	
240/0.3),	 a	 10-fold	 decrease	 of	 the	 IC50	 value	 was	 observed.	 Nevertheless,	 the	 improved	465	
binding	was	associated	with	a	decrease	in	LE	showing	that	the	fragment-enzyme	interactions	466	
are	 less	efficient	with	 the	merged	compounds.	The	reduction	 in	LE	probably	 relates	 to	 the	467	
rigid	structure	of	the	merged	compounds	allowing	for	little	conformational	freedom.	Overall,	468	












36*	 2.9	 20	 0.27	
	 	
37	 48	 70	 0.21	
	 	
38*	 110	 70	 0.19	
	 	
39	 100	 70	 0.22	
	 	































binding	 was	 observed.	 The	 crystal	 structure	 of	 the	 complex	 OXA-48:36	 with	 an	 omit-type	478	
polder-map	 (2.5σ)	 (C)	 and	 its	 2D-representation	 (D)	 shows	 one	 of	 the	 acetamide-groups	479	
interacted	with	the	guanidine	group	of	Arg214,	while	the	other	group	was	solvent	exposed.		480	
The	 structural	 analysis	 of	 the	 OXA-48	 complexes	 with	 36,	 38	 and	 40	 showed	 that	 the	481	
interaction	 of	 the	 carboxylic	 acid	 with	 Arg214	 is	 maintained.	 For	 compound	 36,	 a	 near	482	
perfect	overlay	was	obtained	with	the	complex	structure	of	 fragment	21a	 showing	that	all	483	
interactions	seen	with	the	fragments	were	preserved	in	the	larger	compound	(Fig.	10).	The	484	
second	 3-N-acetamidophenyl	 group	 forms	 a	 not	 previously	 observed	 hydrogen	 bond	with	485	
Ser244.	 In	the	SPR	sensorgrams	some	concentration	dependent	aggregation	was	observed.	486	
(30)	487	
Interestingly,	 the	 conformation	 of	 compound	 38	 in	 complex	 with	 OXA-48	 was	 changed	488	
compared	 with	 the	 mono-substituted	 fragment	 28.	 In	 the	 OXA-48:38	 complex,	 one	489	
quinolinyl	 group	 bound	 in	 the	 R1	 site	 similar	 to	 fragment	21a.	 The	 other	 quinolinyl	 group	490	












was	 prepared	 and	 biochemically	 analysed	 for	 their	 inhibitory	 activity	 against	 OXA-48.	501	
Enzyme-fragment	complexes	for	crystallographic	studies	were	obtained	for	33	fragments.	By	502	
systematically	changing	the	substituent-groups	of	the	benzoic	acid	derivatives	we	were	able	503	
to	 identify	 inhibitory	 fragments	with	 IC50	 <	 40	µM	 (21a,	 26b,	 35).	 Based	on	 the	 structural	504	
information,	fragments	could	be	classified	according	to	their	preferred	binding	pocket.	Most	505	
fragments	 were	 orientated	 towards	 the	 R2	 site	 induced	 by	 a	 π-π-stacking	 with	 Tyr221.	506	
Unfortunately,	no	further	interactions	in	the	R2	site	could	be	identified	from	our	library.	The	507	
strongest	binding	fragments	21a	and	26b	were	binding	in	the	R1	site	due	to	a	hydrogen	bond	508	
to	Arg214	and	 for	 fragment	35	 a	hydrogen	bond	 to	 the	 carbonyl	backbone	of	 Tyr117	was	509	
observed.	By	overlaying	the	complex	crystal	structures	of	fragments	1,	21a,	26b,	28	and	35,	510	
the	design	of	 five	new	3,5-disubstituted	 inhibitors	evolved.	The	strongest	3,5-disubstituted	511	























or	 ester	 (1.5	 equiv)	 and	 potassium	 phosphate	 (5.0	 equiv)	 were	 added.	 The	 solution	 was	533	
degassed	by	vacuum/Argon	cycles	(10	times)	before	addition	of	PdCl2(PPh3)2	(10	mol%)	and	534	
further	 degassed	 (5	 times).	 The	 resulting	 mixture	 was	 stirred	 at	 95	 °C	 under	 argon	535	
atmosphere	 for	 16-20	hours.	 The	 reaction	mixture	was	 filtered	 through	Celite	 and	diluted	536	
with	 water	 (approx.	 30	 mL)	 before	 washing	 with	 chloroform	 (3	 x	 30	 mL).	 If	 not	 stated	537	
otherwise,	 the	aqueous	phase	was	concentrated	under	 reduced	pressure	and	applied	 to	a	538	





The	 halo	 aryl	 (1.0	 equiv)	 was	 dissolved	 in	 anhydrous	 THF.	 The	 aryl	 boronic	 acid	 or	 aryl	542	
boronic	 ester	 (1.5	 equiv)	 and	 inorganic	 base	 (5.0	 equiv)	 were	 added.	 The	 solution	 was	543	
degassed	 by	 vacuum/Argon	 cycles	 (10	 times),	 before	 addition	 of	 a	 palladium	 catalyst	 (10	544	
mol%)	and	further	degassed	(5	times).	The	resulting	mixture	was	stirred	at	75–90	°C	under	545	
an	 inert	atmosphere	for	16-20	hours.	The	reaction	mixture	was	filtered	through	Celite	and	546	
diluted	with	water	 (approx.	 30	mL)	 before	washing	with	 ethyl	 acetate	 (3	 x	 30	mL).	 If	 not	547	
stated	otherwise,	the	aqueous	phase	was	concentrated	under	reduced	pressure	and	applied	548	




3-Bromo-5-iodobenzoic	 acid	 (0.03–0.06	 mmol,	 1.0	 equiv.)	 was	 dissolved	 in	 the	 indicated	553	
solvent	(0.5–1	mL/0.01	mmol	substrate).	The	boronic	acid	or	ester	(1.5	equiv.)	and	base	(5.0	554	
equiv.)	 were	 added.	 The	 solution	 was	 degassed	 by	 vacuum/Ar	 cycles	 (10	 times)	 before	555	
addition	of	the	palladium	catalyst	and	further	degassed	(5	times).	The	resulting	mixture	was	556	


























3,5-Dibromobenzoic	 acid	 (1.01	mmol,	 300	mg,	 1.0	 equiv),	 3-acetamidophenylboronic	 acid	581	
(0.81	mmol,	178	mg,	0.75	equiv),	potassium	phosphate	(3.76	mmol,	0.80	g,	3.5	equiv)	and	582	
PdCl2(PPh3)2	(0.11	mmol,	77	mg,	10	mol%)	were	stirred	in	a	mixture	of	water/dioxane	(1:1)	583	













3,5-Dibromobenzoic	 acid	 (0.11	 mmol,	 33	 mg,	 1.0	 equiv),	 6-quinolinylboronic	 acid	 pinacol	597	
ester	(0.23	mmol,	60	mg,	2.0	equiv),	potassium	phosphate	(0.58	mmol,	125	mg,	5.0	equiv)	598	
were	dissolved	 in	 tert-butanol.	 The	 solution	was	degassed	by	vacuum/Ar	cycles	 (10	 times)	599	
before	addition	of	XPhos-Pd	G2	(5	mol%,	5	mg)	and	further	degassed	(5	times).	The	resulting	600	
mixture	 was	 stirred	 at	 60	 °C	 for	 20–24	 hours.	 The	 reaction	mixture	 was	 filtered	 through	601	
Celite	bed	and	diluted	with	water	(approx.	30	mL)	before	washing	with	chloroform	(3	x	30	602	
mL).	 The	 aqueous	 phase	was	 concentrated	 under	 reduced	 pressure	 and	 applied	 to	 a	 C18	603	
precolumn	 before	 purification	 by	 C18	 RP	 flash	 chromatography	 with	 a	 gradient	 of	604	









3,5-Dibromobenzoic	 acid	 (1.01	mmol,	 300	mg,	 1.0	 equiv),	 3-acetamidophenylboronic	 acid	614	
(0.81	mmol,	178	mg,	0.75	equiv),	potassium	phosphate	(3.76	mmol,	0.80	g,	3.5	equiv)	and	615	
PdCl2(PPh3)2	(0.11	mmol,	77	mg,	10	mol%)	were	stirred	in	a	mixture	of	water/dioxane	(1:1)	616	
for	 24	 hours	 at	 95	 °C	 under	 argon	 atmosphere.	 The	 crude	 reaction	 mixture	 was	 filtered	617	
through	Celite	and	diluted	with	water	(approx.	30	mL)	before	washing	with	chloroform	(3	x	618	
30	mL).	The	aqueous	phase	was	concentrated	under	reduced	pressure	and	applied	to	a	C18	619	
precolumn	 before	 purification	 by	 C18	 RP	 flash	 chromatography	 with	 a	 gradient	 of	620	
acetonitrile	 in	water	 (10–100	%	over	12	minutes).	The	 fractions	were	analysed	by	MS	and	621	
-23-	
	
fractions	 containing	 int-39	were	 combined	and	 reacted	with	pyridin-4-ylboronic	 acid	 (0.97	622	
mmol,	 119	 mg,	 1.2	 equiv),	 potassium	 phosphate	 (4.05	 mmol,	 0.86	 g,	 5.0	 equiv)	 and	623	








ester	 (0.22	 mmol,	 58	 mg,	 1.5	 equiv)	 and	 potassium	 phosphate	 (0.76	 mmol,	 162	 mg,	 5.0	632	
equiv)	 were	 dissolved	 in	 a	mixture	 of	 water/dioxane	 (1:1).	 The	 solution	was	 degassed	 by	633	
vacuum/Ar	cycles	(10	times)	before	addition	of	Pd2(dba)3•CHCl3	(5	mol%,	7.5	mg),	and	SPhos	634	
(5	mol%,	3.1	mg)	and	further	degassed	(5	times).	The	resulting	mixture	was	stirred	at	60	°C	635	






1H),	7.97-7.96	 (m,1H),	7.59-7.56	 (dd,	 J	 =	8.3,	4.2	Hz,	1H).	 13C	NMR	 (101	MHz,	DMSO-d6)	δ	642	
166.6,	 150.8,	 147.2,	 143.6,	 140.6,	 136.8,	 136.5,	 131.7,	 131.1,	 129.6,	 128.5,	 128.2,	 127.4,	643	
126.5,	 125.8,	 121.9,	 121.7;	 HRMS	 (ESI):	 Calcd.	 for	 C16H979BrNO2	 [M-H]–	 325.9822;	 found	644	
325.9822.	645	
4.1.4.3 3-(3'-Acetamidophenyl)-5-quinolin-6-ylbenzoic	acid	40:	646	
3-Bromo-5-(quinolin-6-yl)	 benzoic	 acid	 int-40	 (0.039	 mmol,	 13	 mg,	 1.0	 equiv),	 3-647	
acetamidophenylboronic	acid	(0.55	mmol,	10	mg,	1.5	equiv)	and	potassium	phosphate	(0.20	648	
mmol,	 0.42	 g,	 5.0	 equiv)	 were	 dissolved	 in	 tert-butanol.	 The	 solution	 was	 degassed	 by	649	
vacuum/Ar	cycles	 (10	times)	before	addition	of	Xphos-Pd	G2	(5	mol%,	1.5	mg)	and	further	650	
degassed	(5	times).	The	resulting	mixture	was	stirred	at	60	°C	for	20–24	hours.	The	reaction	651	
mixture	 was	 filtered	 through	 Celite	 bed	 and	 diluted	 with	 water	 (approx.	 30	 mL)	 before	652	
washing	with	chloroform	(3	x	30	mL).	The	aqueous	phase	was	concentrated	under	reduced	653	
pressure	and	applied	to	a	C18	precolumn	before	purification	on	a	60	g	C18	column	with	a	654	





140.8,	 140.7,	 140.5,	 138.8,	 130.8,	 130.4,	 130.3,	 129.7,	 128.6,	 128.5,	 128.5,	 127.0,	 123.9,	660	









All	 experiments	 were	 performed	 using	 a	 Spectramax	 M2e	 at	 25	 °C	 in	 100	 mM	 sodium	668	
phosphate	 (pH	 7.0)	 supplemented	 with	 50	 mM	 NaHCO3	 and	 0.2	 mg/ml	 bovine	 serum	669	
albumin	 (BSA).	 Velocities	 from	 the	 linear	 range	 were	 determined	 in	 the	 SoftMax	 Pro	670	
software	(Molecular	Devices).	All	experiments	were	done	with	a	sample	volume	of	100	μL.	671	
IC50 values	 were	 determined	 for	 all	 compounds	 in	 competition	 with	 25	 µM	 of	 the	672	




All	 SPR	experiments	were	performed	on	a	Biacore	T200	at	 25	 °C.	 The	data	were	analyzed	677	
using	Biacore	T200	Evaluation	Software	2.0	(GE	Healthcare).	The	sensorgrams	were	double	678	
reference	subtracted	using	a	reference	surface	and	blank	injections.	 The	final	running	buffer	679	




60	 s	 dissociation	 time.	 Compounds	 exhibiting	 kinetic	 behavior	 had	 the	 dissociation	 time	684	
extended	to	300	s.	Seven	startup	cycles	with	buffer	were	performed.	Solvent	correction	was	685	
performed	every	48th	cycle	and	a	positive	control	was	included	every	24th	cycle	with	3.5-Di(4-686	




A	 solution	 of	 NaH13CO3	 in	 D2O	 (50	 mM)	 was	 prepared.	 The	 NaH13CO3/D2O-mixture	 was	691	
added	to	1	mM	OXA-48	in	50	mM	sodium	phosphate	and	50	mM	sodium	bicarbonate	pH	6.5	692	
in	a	1	 :	9	 ratio	of	bicarbonate	 to	enzyme.	Compounds	were	diluted	 from	a	150	mM	stock	693	
solution	in	100%	DMSO	to	a	final	concentration	of	3.75	mM	(2.5%	DMSO).	Sample	volumes	694	
of	500	µL	were	used.	We	performed	 the	experiment	at	37	 °C	with	a	Bruker	Avance	 III	HD	695	
with	 an	 inverse	 detected	 TCI	 probe	 with	 cryogenic	 enhancement	 for	 1H,	 13C	 and	 2H,	696	
operating	at	599.90	MHz	for	protons	and	150.86	MHz	for	carbon.	10	000	scans	at	30°	pulse	697	
angle	 with	 2	 s	 relaxation	 delay	 were	 collected	 using	 1D	 13C	 NMR	 with	 power-gated	698	
decoupling	of	protons	(zgpg30	using	waltz16).	699	
4.6 Crystallization	and	data	processing	700	
Crystals	of	OXA-48	was	grown	 from	hanging	drops	 containing	0.1	M	HEPES	pH	7.5,	 8-11%	701	












at	 the	beamlines,(33-37)	but	 in	some	cases	we	 found	 it	useful	 to	 reprocess	using	DIALS	or	712	
XDS	together	with	AIMLESS.(38-40)		713	
The	 compounds	 were	 built	 into	 difference	 density	 maps	 after	 initial	 refinement	 in	714	
phenix.refine,(41)	with	waters	 deleted	 from	 the	 active	 site.	 Restraints	 for	 the	 compounds	715	






and	 The	 Norwegian	 Research	 Council	 (FRIMEDBIO	 project	 number	 213808).	 Provision	 of	722	
beam	 time	 at	 BL14.1	 and	BL14.2,	 Bessy	 II,	 Berlin,	Germany,	 and	 the	MX	beamlines	 at	 the	723	
European	Radiation	Facility	(ESRF),	Grenoble,	France	are	highly	valued.		724	
PDB	accession	codes:	725	
Coordinates	 and	 structure	 factors	 for	 all	 OXA-48	 complexes	 are	 deposited	 in	 the	 Protein	726	
Data	Bank.	Accession	numbers	are	 listed	with	reference	to	the	complexed	compound.	PDB	727	






Supplementary	 material	 containing	 synthetic	 procedures	 and	 analytical	 data	 for	 all	734	
compounds	 and	 biophysical,	 biochemical	 and	 structural	 analysis	 of	 OXA-48:compound	735	
complexes.	736	
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